MedTrace Logo

A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax

NCT06365073 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-04-15

No results posted yet for this study

Summary

This study is a clinical, multi-center, retrospective, case-control study. Patients clinically diagnosed with severe anthrax who meet the inclusion and exclusion criteria will be included in this study for analysis. Respiratory, circulation, nerve and other vital signs of patients with severe anthrax during hospitalization were recorded, and clinical data such as blood routine, blood biochemistry, coagulation function, myocardial injury, therapeutic drug use, and survival time of patients were recorded, as well as the survival situation of patients 28 days and 90 days after discharge.

Conditions

  • Anthrax

Sponsors & Collaborators

  • Qin Ning

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-13
Primary Completion
2024-08-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06365073 on ClinicalTrials.gov